1. Home
  2. BLX vs NTLA Comparison

BLX vs NTLA Comparison

Compare BLX & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Latinoamericano de Comercio Exterior S.A.

BLX

Banco Latinoamericano de Comercio Exterior S.A.

HOLD

Current Price

$51.92

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$13.06

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLX
NTLA
Founded
1977
2014
Country
Panama
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.5B
IPO Year
1997
2016

Fundamental Metrics

Financial Performance
Metric
BLX
NTLA
Price
$51.92
$13.06
Analyst Decision
Buy
Analyst Count
0
20
Target Price
N/A
$20.45
AVG Volume (30 Days)
119.0K
3.1M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
5.26%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
$14.22
N/A
Revenue Next Year
$9.84
$62.75
P/E Ratio
$8.26
N/A
Revenue Growth
N/A
16.92
52 Week Low
$31.14
$5.90
52 Week High
$52.31
$28.24

Technical Indicators

Market Signals
Indicator
BLX
NTLA
Relative Strength Index (RSI) 65.30 50.95
Support Level $43.50 $12.55
Resistance Level N/A $14.32
Average True Range (ATR) 1.20 0.76
MACD 0.27 -0.04
Stochastic Oscillator 99.30 62.82

Price Performance

Historical Comparison
BLX
NTLA

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: